SynthesisHPB : the official journal of the International Hepato Pancreato Biliary Association2016
A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.
Synthesis in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 118 citations in OpenAlex.
- LaparoscopicAnnals of surgical treatment and research · 2026Article
- Sequential Yttrium-90 radioembolization integrated with multimodal therapy for platinum-resistant ovarian cancer liver metastases.Gynecologic oncology reports · 2026Article
- Article
- Single-photon emission computed tomography functional liver imaging to facilitate reirradiation for liver malignancies: A phase I trial.JHEP reports : innovation in hepatology · 2026Article
- Intraoperative irreversible electroporation for margin accentuation in locally advanced intrahepatic cholangiocarcinoma: a case series.Frontiers in surgery · 2026Article
- Single-center experience comparing glass and resin microspheres in lobar Y-90 SIRT for early- to intermediate-stage hepatocellular carcinoma.EJNMMI research · 2025Article
- Liver hypertrophy techniques: a position paper from the Italian Group of Regenerative and Occlusive Worldwide-used techniques of hepatic Hypertrophy (I GROWtoH).Updates in surgery · 2025Article
- Post-Treatment PET/CT Dosimetry to Predict Contralateral Lobe Hypertrophy After Transarterial Radioembolization for Hepatocellular Carcinoma.Korean journal of radiology · 2025Article
- Augmenting the Future Liver Remnant Prior to Major Hepatectomy: A Review of Options on the Menu.Annals of surgical oncology · 2025Review
- Comprehensive Review of Future Liver Remnant (FLR) Assessment and Hypertrophy Techniques Before Major Hepatectomy: How to Assess and Manage the FLR.Annals of surgical oncology · 2024Review
- Role of liver augmentation prior to hepatic resection - a survey on standards, procedures, and indications in Germany, Switzerland, and Austria.Langenbeck's archives of surgery · 2024Article
- Article
- Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?Seminars in interventional radiology · 2024Review
- Article
- Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases.Journal of clinical medicine · 2023Review
- Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study.Therapeutic advances in gastroenterology · 2023Article
- Interventional radiological therapies in colorectal hepatic metastases.Frontiers in oncology · 2023Review
- New concepts in the treatment of hepatocellular carcinoma.United European gastroenterology journal · 2022Review
- Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival AfterJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurative liver resection is the treatment of choice for both primary and secondary liver malignancies. However, an inadequate future liver remnant (FLR) frequently precludes successful surgery. Portal vein embolization is the gold-standard modality for inducing hypertrophy of the FLR. In recent times, unilobar Yttrium-90 selective internal radiation therapy (SIRT) has been reported to induce hypertrophy of the contralateral, untreated liver lobe. The aim of this study is to review the current literature reporting on contralateral liver hypertrophy induced by unilobar SIRT.
methodsA systematic review of the English-language literature between 2000 and 2014 was performed using the search terms "Yttrium 90" OR "selective internal radiation therapy" OR "radioembolization" AND "hypertrophy".
resultsSeven studies, reporting on 312 patients, were included. Two hundred and eighty four patients (91.0%) received treatment to the right lobe. Two hundred and fifteen patients had hepatocellular carcinoma (HCC), 12 had intrahepatic cholangiocarcinoma, and 85 had liver metastases from mixed primaries. Y90 SIRT resulted in contralateral liver hypertrophy which ranged from 26 to 47% at 44 days-9 months. All studies were retrospective in nature, and heterogeneous, with substantial variations relative to pathology treated, underlying liver disease, dosage and delivery of Y90, number of treatment sessions and time to measurement of hypertrophy.
conclusionUnilobar Y90 SIRT results in significant hypertrophy of the contralateral liver lobe. The rate of hypertrophy seems to be slower than that achieved by other methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.